Gene Expression Correlating With Response To Paclitaxel In Ovarian Carcinoma Xenografts

Below is result for Gene Expression Correlating With Response To Paclitaxel In Ovarian Carcinoma Xenografts in PDF format. You can download or read online all document for free, but please respect copyrighted ebooks. This site does not host PDF files, all document are the property of their respective owners.

Gene expression correlating with response to paclitaxel in

Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts Maria Rosa Bani,1 Maria Ines Nicoletti,1 Nawal W. Alkharouf,2 Carmen Ghilardi,1 David Petersen,2 Eugenio Erba,1 Edward A. Sausville,3 Edison T. Liu,4 and Raffaella Giavazzi1 1Mario Negri Institute for Pharmacological Research, Bergamo

RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the

xenografts in mice. Finally, RTN4 knockdown affected tubulin stability and promoted higher cytotoxic effects with chemo-therapeutic paclitaxel in cancer cells both in vitro and in vivo. In summary, RTN4 is involved in carcinogenesis and repre-sents a molecular candidate that may be targeted to achieve desired antitumor effects in clinics

Gene Section

in recurrent ovarian cancer, correlating with a poor outcome of the patients. TRIM27 protein expression was significantly higher in platinum-resistant than in platinum-sensitive patients (Horio et al., 2012). Recombinant TRIM27 expression enhances chemoresistance of ovarian cancer cells to carboplatin and paclitaxel in culture and xenografts

REVIEW Open Access Normal and cancer stem cells of the human

Ovarian epithelial carcinoma Loss of heterozygosity of PTEN, P53, K-ras, HNPCC mutations. BRCA1 and 2 inactivating mutation. ABCG2 overexpression, β-Catenin expression Early stage: Ovarian surgery. Rarely detected at an early stage, because there is no definitive marker, but a combined immunoassay with six markers

Supporting Information - PNAS

May 19, 2009 2. Bani MR, et al. (2004) Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Mol Cancer Ther 3:111 121. 3. Chen JG, Yang CP, Cammer M, Horwitz SB (2003) Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 63:7891 7899. 4.

An in-tumor genetic screen reveals that the BET bromodomain

spite a high initial response rate (∼80%) to carboplatin and paclitaxel chemotherapy, most such cancers eventually recur, accompanied by acquired resistance to chemotherapy. This his-tory typically results in death within 5 years (1). High-grade se-rous ovarian carcinoma (HGSOC) is the most common form of EOC and accounts for two thirds of